Deferasirox NCT07023666 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 2

Clinical phase

Recruiting

Recruitment status

100

Planned enrollment

2027-06-30

Primary-completion proxy

Executive view

NCT07023666 evaluates Deferasirox in Complication. The disclosed sponsor is Inova Health Care Services, the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is Incidence of Hospitalization for Sickle Cell Disease Related Complications, assessed over Up to 12 months.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07023666 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Complication landscape. Drug & Asset MCP drug_fetch was queried for Deferasirox, while Company & Deal Intelligence MCP organization_fetch was queried for Inova Health Care Services.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07023666	Deferasirox	Phase 2 / Recruiting	Inova Health Care Services	United States	Incidence of Hospitalization for Sickle Cell Disease Related Complications Up to 12 months	2027-06-30
NCT07498309	Iloprost	Phase 3 / Not yet recruiting	Sponsor not reported	France	Opioid consumption 28 days following randomization	2030-03-01
NCT07436767	KL-003	Not Applicable / Not yet recruiting	Hematology Hospital of Chinese Academy of Medical Sciences	Geography not reported	The proportion of subjects who achieve successful engraftment of CD34⁺ cells modified with the βA-T87Q-globin lentivira… From Day 0 to Day 42 after cell infusion	2028-09-30
NCT07432867	MUNC-CD34	Phase 1/2 / Recruiting	Assistance Publique des Hôpitaux de Paris SA	France	Neutrophil recovery within the 24 months following IV infusion of DREAM01	2032-02-01
NCT07431398	Pociredir	Phase 1 / Terminated	Fulcrum Therapeutics, Inc.	United States	Plasma concentration of pociredir under fasted and fed conditions Day 1 through Day 4	2026-06-01

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07023666 is a Phase 2, recruiting study with 100 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.

The primary endpoint is “Incidence of Hospitalization for Sickle Cell Disease Related Complications” over “Up to 12 months.” The retrieved endpoint description is: Total number of participants hospitalized for SCD related complications including vaso-occlusive crises, acute chest syndrome and infection detect the impact of early intervention of cardiac iron overload in patients with Sickle Cell Disease.

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 100 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Complication. These records do not establish direct evidence for NCT07023666 unless the registration number matches.

Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders

Phase 2; n=56; Engraftment = 53 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT01050855

Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease

Phase 3; n=26; TI(at least 16 months) = 8.0 Participant Source: https://pubmed.ncbi.nlm.nih.gov/42274009/

PHASE 1/2 HIBISCUS KIDS STUDY OF ETAVOPIVAT IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE: SAFETY AND EFFICACY FINDINGS FROM THE COMPLETE FIRST COHORT

Phase 1/2; n=25; SAE = One SAE (cholestasis with history of cholelithiasis) required dose interruption, event resolved after cholecystectomy. Source: https://library.ehaweb.org/eha/2026/eha-2026/4206844/bernhards.ogutu.phase.1.2.hibiscus.kids.study.of.etavopivat.in.pediatric.html

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

No exact Drug & Asset MCP profile was returned for the protocol wording “Deferasirox.” The report therefore avoids inferring modality, target or global development stage from the name alone.

No exact Company & Deal Intelligence profile was returned for Inova Health Care Services. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Deferasirox is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07023666
Protocol source: https://clinicaltrials.gov/study/NCT07023666
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.

Deferasirox in Complication is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Incidence of Hospitalization for Sickle Cell Disease Related Complications and 2027-06-30 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP